title: CTRP9 Ameliorates Pulmonary Arterial Hypertension Through Attenuating Inflammation and Improving Endothelial Cell Survival and Function.
abstract: Endothelial dysfunction and inflammation are believed to be 2 primary instigators of pulmonary arterial hypertension (PH). C1q/TNF-related protein 9 (CTRP9) plays important roles in anti-inflammation and improvement of epithelial function. However, the role of CTRP9 in the progression of PH remains still unclear. In this study, the role and mechanism of CTRP9 in the PH progression were explored. First, serum CTRP9 contents and CTRP9 mRNA expression in the pulmonary artery epithelial cells from patients with PH were detected. Our data on enzyme-linked immunosorbent assay and real-time quantitative Polymerase Chain Reaction showed that CTRP9 mRNA and protein content were markedly downregulated in the patients with PH. Then the pcDNA-CTRP9 expression vector or CTRP9 siRNA was transfected into the primary pulmonary artery epithelial cells from the patients with PH in vitro. CTRP9 overexpression significantly improved endothelial NOS protein expression and reduced the secretion of endothelin-1 (ET-1) and matrix metalloproteinase-2 (MMP-2), whereas knockdown of CTRP9 sharply reduced eNOS protein expression and promoted the secretion of ET-1 and MMP-2 in the cultured human epithelial cells. Moreover, the levels of phosphatidylinositol 3-kinase (PI3K) and pAkt were reduced in the epithelial cells and CTRP9 overexpression activated the PI3K/Akt pathway. CTRP9 could inhibit cell apoptosis and eNOS expression reduction in the cells pretreated with the PI3K/Akt inhibitor LY294002 and resist LY294002-induced ET-1 and MMP-2 secretion. Finally, to verify the role of CTRP9 in the progression of PH in vivo, the pcDNA-CTRP9 expression vector or CTRP9 siRNA was intravenously injected into rats with PH. Pulmonary arterial pressures of the rats were notably reduced by the pcDNA-CTRP9 injection and elevated by the CTRP9 siRNA injection. In conclusion, CTRP9 ameliorated PH by attenuating inflammation and improving endothelial cell survival and function.
authors.affiliation: Cardiovascular Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Yongxin
authors.initials: Y
authors.lastname: Li
authors.forename: Xigang
authors.initials: X
authors.lastname: Geng
authors.forename: Haichen
authors.initials: H
authors.lastname: Wang
authors.forename: Gesheng
authors.initials: G
authors.lastname: Cheng
authors.forename: Suochun
authors.initials: S
authors.lastname: Xu
mesh_terms: D052242:Adiponectin / Q000096:biosynthesis*; D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D019332:Endothelin-1 / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000276:immunology*; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011651:Pulmonary Artery / Q000276:immunology*; D012333:RNA, Messenger; D051381:Rats; D060888:Real-Time Polymerase Chain Reaction; D047988:Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
chemical_list: D052242:Adiponectin; D002867:Chromones; D019332:Endothelin-1; D006023:Glycoproteins; D020778:Matrix Metalloproteinase 2; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D012333:RNA, Messenger; D047988:Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; C543615:C1QTNF9B protein, human; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one